Updated

Natera CEO Steven Chapman sold 1,698 shares of the genetic testing company for approximately $545,000, according to a regulatory filing disclosure. The sale represents routine executive stock activity rather than a signal of any operational change at the company. Insider sales of this size are typically disclosed under standard reporting requirements and do not necessarily reflect a change in outlook, though they are often tracked by investors monitoring executive sentiment.